Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

36 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Myeloid neoplasms post PARP inhibitors for ovarian cancer.
Caruso G, Gigli F, Parma G, Lapresa M, Derio S, Palaia I, Colombo N. Caruso G, et al. Among authors: lapresa m. Int J Gynecol Cancer. 2023 Apr 3;33(4):598-606. doi: 10.1136/ijgc-2022-004190. Int J Gynecol Cancer. 2023. PMID: 36707087 Review.
Role of conservative surgery in ovarian cancer: the European experience.
Colombo N, Parma G, Lapresa MT, Maggi F, Piantanida P, Maggioni A. Colombo N, et al. Among authors: lapresa mt. Int J Gynecol Cancer. 2005 Nov-Dec;15 Suppl 3:206-11. doi: 10.1111/j.1525-1438.2005.00428.x. Int J Gynecol Cancer. 2005. PMID: 16343232 Free article. Review.
Neoadjuvant chemotherapy in cervical cancer: an update.
Lapresa M, Parma G, Portuesi R, Colombo N. Lapresa M, et al. Expert Rev Anticancer Ther. 2015;15(10):1171-81. doi: 10.1586/14737140.2015.1079777. Epub 2015 Sep 7. Expert Rev Anticancer Ther. 2015. PMID: 26402247 Review.
Risk-reducing Salpingo-Oophorectomy in Women at Higher Risk of Ovarian and Breast Cancer: A Single Institution Prospective Series.
Ricciardi E, Tomao F, Aletti G, Bazzurini L, Bocciolone L, Boveri S, Landoni F, Lapresa MT, Maruccio M, Parma G, Peccatori F, Petrella MC, Zanagnolo V, Colombo N, Maggioni A. Ricciardi E, et al. Among authors: lapresa mt. Anticancer Res. 2017 Sep;37(9):5241-5248. doi: 10.21873/anticanres.11948. Anticancer Res. 2017. PMID: 28870960 Free article.
Carboplatin-paclitaxel compared to Carboplatin-Paclitaxel-Bevacizumab in advanced or recurrent endometrial cancer: MITO END-2 - A randomized phase II trial.
Lorusso D, Ferrandina G, Colombo N, Pignata S, Pietragalla A, Sonetto C, Pisano C, Lapresa MT, Savarese A, Tagliaferri P, Lombardi D, Cinieri S, Breda E, Sabatucci I, Sabbatini R, Conte C, Cecere SC, Maltese G, Scambia G. Lorusso D, et al. Among authors: lapresa mt. Gynecol Oncol. 2019 Dec;155(3):406-412. doi: 10.1016/j.ygyno.2019.10.013. Epub 2019 Oct 31. Gynecol Oncol. 2019. PMID: 31677820 Clinical Trial.
Clinical presentation, diagnosis and management of therapy-related hematological disorders in women with epithelial ovarian cancer treated with chemotherapy and poly-ADP-ribose polymerase inhibitors: A single-center experience.
Todisco E, Gigli F, Mantiero M, Sammassimo S, Pastano R, Ronchini C, Parma G, Lapresa MT, Iori AP, Bertolini F, Corsini C, Gregato G, Poletti C, Colombo N, Tarella C. Todisco E, et al. Among authors: lapresa mt. Int J Cancer. 2021 Jan 1;148(1):170-177. doi: 10.1002/ijc.33269. Epub 2020 Sep 16. Int J Cancer. 2021. PMID: 32856727 Free article.
Thromboembolic events and antithrombotic prophylaxis in advanced ovarian cancer patients treated with bevacizumab: secondary analysis of the phase IV MITO-16A/MaNGO-OV2A trial.
Di Liello R, Arenare L, Raspagliesi F, Scambia G, Pisano C, Colombo N, Frezzini S, Tognon G, Artioli G, Gadducci A, Lauria R, Ferrero A, Cinieri S, De Censi A, Breda E, Scollo P, De Giorgi U, Lissoni AA, Katsaros D, Lorusso D, Salutari V, Cecere SC, Lapresa M, Nardin M, Bogani G, Distefano M, Greggi S, Gargiulo P, Schettino C, Gallo C, Daniele G, Califano D, Perrone F, Pignata S, Piccirillo MC. Di Liello R, et al. Among authors: lapresa m. Int J Gynecol Cancer. 2021 Oct;31(10):1348-1355. doi: 10.1136/ijgc-2021-002786. Epub 2021 Aug 30. Int J Gynecol Cancer. 2021. PMID: 34462317 Clinical Trial.
Randomized phase II trial of weekly paclitaxel vs. cediranib-olaparib (continuous or intermittent schedule) in platinum-resistant high-grade epithelial ovarian cancer.
Colombo N, Tomao F, Benedetti Panici P, Nicoletto MO, Tognon G, Bologna A, Lissoni AA, DeCensi A, Lapresa M, Mancari R, Palaia I, Tasca G, Tettamanzi F, Alvisi MF, Rulli E, Poli D, Carlucci L, Torri V, Fossati R, Biagioli E; BAROCCO study group. Colombo N, et al. Among authors: lapresa m. Gynecol Oncol. 2022 Mar;164(3):505-513. doi: 10.1016/j.ygyno.2022.01.015. Epub 2022 Jan 19. Gynecol Oncol. 2022. PMID: 35063281 Clinical Trial.
36 results